My Blog

Tag: Care Plans, Pathophysiology & Pharmacology

  • [Solved] Nursing

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    In-depth study guidance and analytical solution covering Nursing.

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Full assignment prompt and step-by-step guidance are included in the downloadable solution file.

  • [Solved] Bm week 5

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    Bm week 5 **Introduction** 1. You are going to construct an APA formatted paper for the assignment. 2. Provide an APA formatted title page. 3. Develop an introduction section that includes the professional nurses’ role in using evidence from the literature to address a practice problem. 4. Provide a…

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Bm week 5

    **Introduction**

    1. You are going to construct an APA formatted paper for the assignment.
    2. Provide an APA formatted title page.
    3. Develop an introduction section that includes the professional nurses’ role in using evidence from the literature to address a practice problem.
    4. Provide a review of the practice problem and supporting evidence of its existence and significance using the **primary article only** from the Unit 4 literature list (including any suggested edits from the faculty).
    5. Search for evidence-based interventions from scholarly literature to address this practice problem and choose ONE from this search that is the best intervention if the problem existed in YOUR CLINICAL PRACTICE

    Conduct a search of scholarly literature and select ONE evidence-based intervention that is best to address the practice problem if it existed in YOUR CLINICAL PRACTICE. The intervention should be one that is new, innovative, and/or improves the current standards of care.

    1. Write a Literature Review for your selected intervention supported with three (3) articles.
    2. Synthesize the 3 articles by comparing/contrasting study design, population, results, and limitations/gaps showing the intervention addresses the practice problem.
    3. **NOTE**: the three (3) additional articles for the literature review cannot be articles that are referenced in the primary article you selected from the list in Unit 4.
    4. The 3 additional articles discussing this single intervention will have a publication date within the last 5 to 10 years.
    5. Do not do a summary of each intervention individually. Refer to the video on “Your First Literature Review” for organization of this section.
    6. Explain why this is the best evidence-based intervention for your clinical practice setting.

    7. Develop a conclusion section for the paper that summarizes the content and your thoughts about the significance of the using evidence from the literature to address practice problems.
    8. Provide an APA formatted reference page and include citations for each source in the body of the assignment where appropriate.
    9. The suggested length for this submission, excluding title and reference pages, is no less than 3 pages.

    **The assignment requirements include that you upload a file of the full-text article for each listed reference.NU 700 Unit 5-KTA Part 1: Alternate Intervention Paper (1)** CriteriaRatingsPts **This criterion is linked to a Learning OutcomeTopic Alignment and Critical Thinking60 ptsAdvanced CompetenceThe submission is based on a literature article selected from the Unit 4 list and demonstrates advanced graduate scholarship by comprehensively discussing ALL assignment elements: Introduction: includes the role of the professional nurse in using literature evidence to address a practice problem. Review of Problem • Requested Edits from Unit 4. • Statement of the practice problem • The significance of the problem • The existence of the problem Literature Review: Explains a single evidence-based intervention that is new or improves upon current standards of care with rationale for selection at the student’s practice setting. Conclusion: significance of evidence-based interventions to address practice problems.56 ptsCompetentThe submission is based on a literature article selected from the Unit 4 list and indicates competent graduate scholarship by adequately discussing assignment elements OR one or two elements may be missing or underdeveloped: Introduction: includes the role of the professional nurse in using literature evidence to address a practice problem. Review of Problem: • Requested Edits from Unit 4. • Statement of the practice problem • The significance of the problem • The existence of the problem Literature Review: Explains a single evidence-based intervention and rationale for selection at the student’s practice setting. Conclusion: significance of evidence-based interventions to address practice problems.50 ptsEmerging CompetenceThe submission is based on a literature article selected from the Unit 4 list and indicates graduate scholarship is developing as assignment elements are superficially addressed OR 3 elements are missing or underdeveloped: Introduction: includes the role of the professional nurse in using literature evidence to address a practice problem. Review of Problem: • Requested Edits from Unit 4. • Statement of the practice problem • The significance of the problem • The existence of the problem Literature Review: Explains a single evidence-based intervention and rationale for selection at the student’s practice setting. Conclusion: significance of evidence-based interventions to address practice problems.43 ptsNot CompetentThe submission is NOT based on a literature article selected from the Unit 4 list OR indicates a lack of the critical thinking expected of graduate scholarship as four or more elements are missing or underdeveloped. Introduction: includes the role of the professional nurse in using literature evidence to address a practice problem. Review of Problem: • Requested Edits from Unit 4. • Statement of the practice problem • The significance of the problem • The existence of the problem Literature Review: Explains a single evidence-based intervention and rationale for selection at the student’s practice setting. Conclusion: significance of evidence-based interventions to address practice problems.0 ptsAbsentThe submission was late without an approved extension (per the Makeup Policy) or was not submitted.60 ptsThis criterion is linked to a Learning OutcomeSources and Synthesizes Relevant Evidence60 ptsAdvanced CompetenceThe submission demonstrates exceptional ability to locate, synthesize, and apply current (within 5–10 years) peer-reviewed evidence to address the practice problem and meet assignment requirements AND the literature review provides a comprehensive synthesis of 3 articles comparing/contrasting study design, population, results, and limitations/gaps. AND all sources are retrievable as specified in assignment directions.56 ptsCompetentThe submission demonstrates an adequate ability to locate, synthesize, and apply current (within 5–10 years) peer-reviewed evidence to address the practice problem and meet assignment requirements AND/OR the literature review provides an adequate synthesis of 3 articles mostly comparing/contrasting study design, population, results, and limitations/gaps. AND all sources are retrievable as specified in assignment directions.50 ptsEmerging CompetenceThe submission demonstrates a limited ability to locate or apply current (within 5–10 years) peer-reviewed evidence to address the practice problem as 1 supporting article source may be older than 10 years or come from grey literature AND/OR the submission provides summaries of 3 articles about one intervention. AND all sources are retrievable as specified in assignment directions43 ptsNot CompetentThe submission demonstrates minimal to no ability to locate or apply current (within 5–10 years) peer-reviewed evidence as 2 or 3 of the supporting article sources are older than 10 years or from grey literature AND/OR the analysis does not support the practice problem AND/ OR the submission provides summaries of 3 articles about more than one intervention. AND/OR one or more supporting sources are referenced in the primary article OR one or more sources are NOT retrievable as specified in assignment directions.0 ptsAbsentThe submission was late without an approved extension (per the Makeup Policy) or was not submitted.60 ptsThis criterion is linked to a Learning OutcomeScholarly Writing & Organization20 ptsAdvanced CompetenceThe submission demonstrates exemplary organization with no errors in grammar, spelling or punctuation AND the narrative flows logically with strong transitions that demonstrate clarity, conciseness and fluency relative to the main concepts of the assignment.19 ptsCompetentThe submission demonstrates satisfactory organization; minor grammatical, spelling or punctuation errors are noted AND/OR the narrative flows logically and promotes the ability for the reader to follow the discussion of the main concepts of the assignment.17 ptsEmerging CompetenceThe submission demonstrates limited organization; multiple grammar, spelling or punctuation errors are noted AND/OR the narrative does not flow logically thereby diminishing the ability for the reader to follow the discussion of the main concepts of the assignment.14 ptsNot CompetentThe submission does not demonstrate organization and structure consistent with graduate scholarship expectations.0 ptsIncompleteThe submission was late without an approved extension (per the Makeup Policy) or was not submitted.20 ptsThis criterion is linked to a Learning OutcomeAPA Formatting10 ptsAdvanced CompetenceThe formatting in the submission is consistent with current APA guidelines and free of readily identifiable errors.9 ptsCompetentThe formatting in the submission is consistent with current APA guidelines with only minor errors noted.8 ptsEmerging CompetenceThe formatting in the submission is not consistently aligned with current APA guidelines and /or multiple errors are noted.7 ptsNot CompetentThe formatting in the submission is not aligned with current APA guidelines.0 ptsAbsentThe submission was late without an approved extension (per the Makeup Policy) or was not submitted.**

    – [\
    \
    MedicationErrorsDuringHospitalAdmissionandDischarge.docx](https://www.sweetstudy.com/files/medicationerrorsduringhospitaladmissionanddischarge-docx "MedicationErrorsDuringHospitalAdmissionandDischarge.docx")

  • [Solved] Assiganment 2

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    In-depth study guidance and analytical solution covering Assiganment 2.

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Full assignment prompt and step-by-step guidance are included in the downloadable solution file.

  • [Solved] ASSESSMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 2

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    FIND ATTACHED **files (3)** – ## case.docx – ## ASSESSMECARDIOVASCULARSYSTEMPATIENTCASEPART2.docx – ## MD1Assgn1_Edobor_J.docx **## case.docx** KU is a 47 year old male following up on his lab that were drawn last week. He smokes 1 pack per day. He is currently on lisinopril 40mg po daily, liraglu…

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    FIND ATTACHED

    **files (3)**

    – ## case.docx

    – ## ASSESSMECARDIOVASCULARSYSTEMPATIENTCASEPART2.docx

    – ## MD1Assgn1_Edobor_J.docx

    **## case.docx**

    KU is a 47 year old male following up on his lab that were drawn last week. He smokes 1 pack per day. He is currently on lisinopril 40mg po daily, liraglutide (Victoza) 0.6mg subcutaneously once daily and St. John's Wort. Fasting lipid profile shows total cholesterol 260mg/dL, LDL 180mg/dL, and TG 185mg/dL. He is 5'9' and weights 204lbs.

    **## ASSESSMECARDIOVASCULARSYSTEMPATIENTCASEPART2.docx**

    ASSESSMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 2

    ![A computer with a paper on it AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    In Part 2 of the Cardiovascular System Patient Case, you will synthesize your learning into a succinct
    **elevator speech**, presenting your patient plan and reflecting on how new insights from the module inform your clinical approach.

    This assignment challenges you to
    **communicate complex pharmacotherapeutic decisions** clearly and concisely, demonstrating your ability to
    **adapt treatment strategies** based on evolving evidence and patient needs. Use the study questions to identify key information and ensure your presentation is both comprehensive and focused.

    ![A blue and white logo AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    **Level 1: No AI Permitted**

    · AI tools may
    **not** be used at any stage

    · Common for clinical documentation or performancebased work

    RESOURCES

    Be sure to review the Learning Resources before completing this assessment.

    [Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290075?module_item_id=9903145)

    **To prepare:**

    · Complete the Cardiovascular System Patient Case, Part 1

    · Consider the important information to present from your patient plan

    BY SUNDAY OF WEEK 2

    Submit a 3-minute elevator speech recording using a slide deck to highlight the important information from your patient plan.

    Imagine you are giving your preceptor an update on the case. In your presentation, explore how your treatment plan would change based on what you learned this week. This presentation should be no more than 3 minutes.

    ## image1.png

    ## image2.png

    **## MD1Assgn1_Edobor_J.docx**

    1

    ## Patient Case Study Template

    Jane Edobor

    Walden University

    Dr Veleka Grady

    Advance pharmacology

    May 29, 2026

    ## Patient Case Study Template

    ### 1. Patient Profile

    ·
    **Age:** 47 years

    ·
    **Gender:** Male

    ·
    **Ethnicity:** Not specified

    ·
    **Relevant Genetics (if available):** None reported, no familial hypercholesterolemia or markers for statin sensitivity (e.g., SLCO1B1 variants).

    ·
    **Behavioral Factors (e.g., smoking, alcohol, adherence):** Current smoker, approximately 25 pack years; Not specified, alcohol use; Adherence, not documented, lisinopril, liraglutide (which is an herbal supplement used for mood); Current, takes St. John's wort daily.

    ·
    **Relevant Medical History:** Hypertension (on lisinopril 40 mg daily) and type 2 diabetes (on liraglutide 0.6 mg subcutaneously daily).

    ·
    **Current Diagnoses:**

    · Severe hypercholesterolemia (LDL 180mg/dL)

    · Mixed hyperlipidaemia (total cholesterol = 260 mg/dL, TG = 185 mg/dL)

    · Diabetes + hypertension + smoking + obesity is considered to be high-risk atherosclerotic cardiovascular disease (ASCVD) equivalent.

    · Overweight/obesity (height 5’9”, weight 204 lbs → BMI ≈ 30.1 kg/m²)

    ·
    **Pathophysiological Changes (e.g., renal, heart, or liver failure):** No renal failure, heart failure or liver failure reported; diabetes causes endothelial dysfunction, accelerated atherosclerosis, and LDL particle retention; smoking causes LDL to oxidize and HDL to decrease; cardiovascular benefit of liraglutide is not fully compensated for by dyslipidemia.

    ### 2. Medication Plan

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dosage and Route:** 40 mg orally

    ·
    **Frequency:** Once daily in the evening

    ·
    **Rationale for Selection (including patient-specific factors):** Atorvastatin 40 mg is a high-intensity statin, which lowers LDL by ≥50% (Grundy et al., 2019). The 2018 ACC/AHA cholesterol guideline recommends that persons with diabetes age 40-75 years who have multiple ASCVD risk factors (e.g. hypertension, smoking, obesity, LDL ≥70 mg/dL) should be treated with high-intensity statin therapy, even without the use of a risk calculator (Bhattacharya, 2026). Another risk factor for this patient is his LDL of 180 mg/dL, which is considered severe (LDL ≥190 mg/dL is considered severe; 180 mg/dL is borderline severe with multiple risks). The use of a statin is equally beneficial irrespective of age, gender or ethnicity, as would be further increased at 47 years and male (if applicable) and African American ethnicity (if applicable). Atorvastatin is more commonly used than simvastatin as this is a moderate dose and simvastatin 80mg is no longer recommended as it carries the risk of myopathy. Furthermore, there is greater and more stable LDL lowering with atorvastatin. Most importantly, the patient should stop taking St. John's wort, which is a strong inducer of CYP3A4, and decreases the serum levels of atorvastatin and the reduction in LDL.

    ·
    **Potential Drug Interactions or Contraindications:**

    · St. John's wort is an inducer of CYP3A4 which decreases atorvastatin AUC by ~40% and may result in therapeutic failure and ongoing high ASCVD risk (Chan et al., 2025).

    · No contraindications with lisinopril or liraglutide.

    · Smoking by itself does not interact directly, it does however increase LDL oxidation and decrease HDL.

    · Stay away from gemfibrozil (risks of myopathy); good old fenofibrate can be used if triglycerides are still > 500 mg/dL.

    · Relative contraindication: Active liver disease (not reported).

    ·
    **Monitoring Parameters:**

    · Baseline: Lipid panel, liver function tests (ALT, AST), creatine kinase (CK)

    · Repeat lipid profile after 4–12 weeks to evaluate LDL response to treatment and adherence (Bhattacharya, 2026).

    · Ongoing: CK only if patient complains of unexplainable muscle pain, weakness or dark urine.

    · Once every 6-12 months: LFTs; stop if ALT/AST is more than 3 times the upper limit of normal.

    · Behavioral Monitoring: Evaluate smoking status and St. John's wort use at each patient visit.

    ### 3. Ethical and Legal Considerations

    Several ethical and legal principles apply to KU’s personalized medication plan.

    · Informed consent: Provider needs to explain that St. John's wort decreases the effectiveness of atorvastatin in lowering LDL cholesterol, thus the risk of heart attack or stroke (Mefford et al., 2021). The patient can refuse to stop the herb but the provider should record this decision and think about using an alternative statin that is not as reliant on CYP3A4 such as pravastatin (which is less effective).

    · Patient autonomy is recognized by offering evidence-based choices, rather than pressuring. When prescribing St. John's wort, the provider may still prescribe atorvastatin, but will have to monitor and counsel for residual risk if KU decides to continue prescribing St. John's wort.

    · Cultural sensitivity: Some patients take herbal medicines such as St. John's wort in the context of their culture belief. The provider should enquire about the use of supplements in a respectful way, without using judgmental language, and should recognize that some patients may not be accepting conventional treatment, and have a distrust of it.

    · Legal issues: The prescriber (NP or physician) must practice within the scope of practice for statins in their state, and have the power to stop prescribing supplements. Not checking for herb-drug interactions may be a failure to meet the standard of care and be legally liable (Guyton, 2021). Moreover, it's legal to document counselling on smoking cessation, as smoking is a risk factor that can be modified, and statins don't fully counteract it.

    · Equity and conformance to guidelines: The ACC/AHA guidelines apply to all ethnicities/genders and the cost and accessibility shouldn't be barriers (atorvastatin is generic and low cost) (Blumenthal et al., 2026).

    ### 4. Complete Medication Order

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dose:** 40 mg

    ·
    **Route:** Oral

    ·
    **Frequency:** Once a day in the evening

    ·
    **Special Instructions:**

    · Stop St. John's wort because of important drug interaction that decreases the cholesterol-lowering effect.

    · May be taken with or without food. Dosage in the evening might be more beneficial to the reduction of LDL.

    · Have fasted blood lipid panel and liver function tests repeated in 6 weeks.

    · Call a doctor for any unexplained muscle pain or tenderness, weakness, or dark-colored urine or fatigue.

    · Strongly recommend smoking cessation counseling – refer to tobacco cessation program.

    · Use lisinopril 40 mg once a day and liraglutide 0.6 mg subcutaneously once daily, as needed.

    ## References

    Bhattacharya, R. (2026).
    _New cholesterol guidelines | mass general brigham_. Massgeneralbrigham.org. https://www.massgeneralbrigham.org/en/about/newsroom/articles/new-cholesterol-guidelines

    Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., & Mora, S. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.
    _JACC_,
    _87_(19). https://doi.org/10.1016/j.jacc.2025.11.016

    Chan, W.-J. J., Hunter, J., McLachlan, A. J., & Harnett, J. E. (2025). Consumer purchasing behaviour: oral contraceptives with Hypericum perforatum, and atorvastatin with Camellia sinensis: an Australia-wide basket analysis.
    _Drugs & Therapy Perspectives_,
    _41_, 354–362. https://doi.org/10.1007/s40267-025-01167-z

    Guyton, J. R. (2021). From the editor: Plagues and the ancient legacy of epimenides.
    _Journal of Clinical Lipidology_,
    _14_(3), 271–272. https://doi.org/10.1016/j.jacl.2020.05.004

    Mefford, B., Donaldson, J. C., & Bissell, B. D. (2021). The immunomodulatory effects of opioids and implications for intensive care unit populations.
    _Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy_,
    _41_(8), 668–675. https://doi.org/10.1002/phar.2602

    **## MD1Assgn1_Edobor_J.docx**

    1

    ## Patient Case Study Template

    Jane Edobor

    Walden University

    Dr Veleka Grady

    Advance pharmacology

    May 29, 2026

    ## Patient Case Study Template

    ### 1. Patient Profile

    ·
    **Age:** 47 years

    ·
    **Gender:** Male

    ·
    **Ethnicity:** Not specified

    ·
    **Relevant Genetics (if available):** None reported, no familial hypercholesterolemia or markers for statin sensitivity (e.g., SLCO1B1 variants).

    ·
    **Behavioral Factors (e.g., smoking, alcohol, adherence):** Current smoker, approximately 25 pack years; Not specified, alcohol use; Adherence, not documented, lisinopril, liraglutide (which is an herbal supplement used for mood); Current, takes St. John's wort daily.

    ·
    **Relevant Medical History:** Hypertension (on lisinopril 40 mg daily) and type 2 diabetes (on liraglutide 0.6 mg subcutaneously daily).

    ·
    **Current Diagnoses:**

    · Severe hypercholesterolemia (LDL 180mg/dL)

    · Mixed hyperlipidaemia (total cholesterol = 260 mg/dL, TG = 185 mg/dL)

    · Diabetes + hypertension + smoking + obesity is considered to be high-risk atherosclerotic cardiovascular disease (ASCVD) equivalent.

    · Overweight/obesity (height 5’9”, weight 204 lbs → BMI ≈ 30.1 kg/m²)

    ·
    **Pathophysiological Changes (e.g., renal, heart, or liver failure):** No renal failure, heart failure or liver failure reported; diabetes causes endothelial dysfunction, accelerated atherosclerosis, and LDL particle retention; smoking causes LDL to oxidize and HDL to decrease; cardiovascular benefit of liraglutide is not fully compensated for by dyslipidemia.

    ### 2. Medication Plan

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dosage and Route:** 40 mg orally

    ·
    **Frequency:** Once daily in the evening

    ·
    **Rationale for Selection (including patient-specific factors):** Atorvastatin 40 mg is a high-intensity statin, which lowers LDL by ≥50% (Grundy et al., 2019). The 2018 ACC/AHA cholesterol guideline recommends that persons with diabetes age 40-75 years who have multiple ASCVD risk factors (e.g. hypertension, smoking, obesity, LDL ≥70 mg/dL) should be treated with high-intensity statin therapy, even without the use of a risk calculator (Bhattacharya, 2026). Another risk factor for this patient is his LDL of 180 mg/dL, which is considered severe (LDL ≥190 mg/dL is considered severe; 180 mg/dL is borderline severe with multiple risks). The use of a statin is equally beneficial irrespective of age, gender or ethnicity, as would be further increased at 47 years and male (if applicable) and African American ethnicity (if applicable). Atorvastatin is more commonly used than simvastatin as this is a moderate dose and simvastatin 80mg is no longer recommended as it carries the risk of myopathy. Furthermore, there is greater and more stable LDL lowering with atorvastatin. Most importantly, the patient should stop taking St. John's wort, which is a strong inducer of CYP3A4, and decreases the serum levels of atorvastatin and the reduction in LDL.

    ·
    **Potential Drug Interactions or Contraindications:**

    · St. John's wort is an inducer of CYP3A4 which decreases atorvastatin AUC by ~40% and may result in therapeutic failure and ongoing high ASCVD risk (Chan et al., 2025).

    · No contraindications with lisinopril or liraglutide.

    · Smoking by itself does not interact directly, it does however increase LDL oxidation and decrease HDL.

    · Stay away from gemfibrozil (risks of myopathy); good old fenofibrate can be used if triglycerides are still > 500 mg/dL.

    · Relative contraindication: Active liver disease (not reported).

    ·
    **Monitoring Parameters:**

    · Baseline: Lipid panel, liver function tests (ALT, AST), creatine kinase (CK)

    · Repeat lipid profile after 4–12 weeks to evaluate LDL response to treatment and adherence (Bhattacharya, 2026).

    · Ongoing: CK only if patient complains of unexplainable muscle pain, weakness or dark urine.

    · Once every 6-12 months: LFTs; stop if ALT/AST is more than 3 times the upper limit of normal.

    · Behavioral Monitoring: Evaluate smoking status and St. John's wort use at each patient visit.

    ### 3. Ethical and Legal Considerations

    Several ethical and legal principles apply to KU’s personalized medication plan.

    · Informed consent: Provider needs to explain that St. John's wort decreases the effectiveness of atorvastatin in lowering LDL cholesterol, thus the risk of heart attack or stroke (Mefford et al., 2021). The patient can refuse to stop the herb but the provider should record this decision and think about using an alternative statin that is not as reliant on CYP3A4 such as pravastatin (which is less effective).

    · Patient autonomy is recognized by offering evidence-based choices, rather than pressuring. When prescribing St. John's wort, the provider may still prescribe atorvastatin, but will have to monitor and counsel for residual risk if KU decides to continue prescribing St. John's wort.

    · Cultural sensitivity: Some patients take herbal medicines such as St. John's wort in the context of their culture belief. The provider should enquire about the use of supplements in a respectful way, without using judgmental language, and should recognize that some patients may not be accepting conventional treatment, and have a distrust of it.

    · Legal issues: The prescriber (NP or physician) must practice within the scope of practice for statins in their state, and have the power to stop prescribing supplements. Not checking for herb-drug interactions may be a failure to meet the standard of care and be legally liable (Guyton, 2021). Moreover, it's legal to document counselling on smoking cessation, as smoking is a risk factor that can be modified, and statins don't fully counteract it.

    · Equity and conformance to guidelines: The ACC/AHA guidelines apply to all ethnicities/genders and the cost and accessibility shouldn't be barriers (atorvastatin is generic and low cost) (Blumenthal et al., 2026).

    ### 4. Complete Medication Order

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dose:** 40 mg

    ·
    **Route:** Oral

    ·
    **Frequency:** Once a day in the evening

    ·
    **Special Instructions:**

    · Stop St. John's wort because of important drug interaction that decreases the cholesterol-lowering effect.

    · May be taken with or without food. Dosage in the evening might be more beneficial to the reduction of LDL.

    · Have fasted blood lipid panel and liver function tests repeated in 6 weeks.

    · Call a doctor for any unexplained muscle pain or tenderness, weakness, or dark-colored urine or fatigue.

    · Strongly recommend smoking cessation counseling – refer to tobacco cessation program.

    · Use lisinopril 40 mg once a day and liraglutide 0.6 mg subcutaneously once daily, as needed.

    ## References

    Bhattacharya, R. (2026).
    _New cholesterol guidelines | mass general brigham_. Massgeneralbrigham.org. https://www.massgeneralbrigham.org/en/about/newsroom/articles/new-cholesterol-guidelines

    Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., & Mora, S. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.
    _JACC_,
    _87_(19). https://doi.org/10.1016/j.jacc.2025.11.016

    Chan, W.-J. J., Hunter, J., McLachlan, A. J., & Harnett, J. E. (2025). Consumer purchasing behaviour: oral contraceptives with Hypericum perforatum, and atorvastatin with Camellia sinensis: an Australia-wide basket analysis.
    _Drugs & Therapy Perspectives_,
    _41_, 354–362. https://doi.org/10.1007/s40267-025-01167-z

    Guyton, J. R. (2021). From the editor: Plagues and the ancient legacy of epimenides.
    _Journal of Clinical Lipidology_,
    _14_(3), 271–272. https://doi.org/10.1016/j.jacl.2020.05.004

    Mefford, B., Donaldson, J. C., & Bissell, B. D. (2021). The immunomodulatory effects of opioids and implications for intensive care unit populations.
    _Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy_,
    _41_(8), 668–675. https://doi.org/10.1002/phar.2602

    **## case.docx**

    KU is a 47 year old male following up on his lab that were drawn last week. He smokes 1 pack per day. He is currently on lisinopril 40mg po daily, liraglutide (Victoza) 0.6mg subcutaneously once daily and St. John's Wort. Fasting lipid profile shows total cholesterol 260mg/dL, LDL 180mg/dL, and TG 185mg/dL. He is 5'9' and weights 204lbs.

    **## ASSESSMECARDIOVASCULARSYSTEMPATIENTCASEPART2.docx**

    ASSESSMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 2

    ![A computer with a paper on it AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    In Part 2 of the Cardiovascular System Patient Case, you will synthesize your learning into a succinct
    **elevator speech**, presenting your patient plan and reflecting on how new insights from the module inform your clinical approach.

    This assignment challenges you to
    **communicate complex pharmacotherapeutic decisions** clearly and concisely, demonstrating your ability to
    **adapt treatment strategies** based on evolving evidence and patient needs. Use the study questions to identify key information and ensure your presentation is both comprehensive and focused.

    ![A blue and white logo AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    **Level 1: No AI Permitted**

    · AI tools may
    **not** be used at any stage

    · Common for clinical documentation or performancebased work

    RESOURCES

    Be sure to review the Learning Resources before completing this assessment.

    [Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290075?module_item_id=9903145)

    **To prepare:**

    · Complete the Cardiovascular System Patient Case, Part 1

    · Consider the important information to present from your patient plan

    BY SUNDAY OF WEEK 2

    Submit a 3-minute elevator speech recording using a slide deck to highlight the important information from your patient plan.

    Imagine you are giving your preceptor an update on the case. In your presentation, explore how your treatment plan would change based on what you learned this week. This presentation should be no more than 3 minutes.

    ## image1.png

    ## image2.png

    **## MD1Assgn1_Edobor_J.docx**

    1

    ## Patient Case Study Template

    Jane Edobor

    Walden University

    Dr Veleka Grady

    Advance pharmacology

    May 29, 2026

    ## Patient Case Study Template

    ### 1. Patient Profile

    ·
    **Age:** 47 years

    ·
    **Gender:** Male

    ·
    **Ethnicity:** Not specified

    ·
    **Relevant Genetics (if available):** None reported, no familial hypercholesterolemia or markers for statin sensitivity (e.g., SLCO1B1 variants).

    ·
    **Behavioral Factors (e.g., smoking, alcohol, adherence):** Current smoker, approximately 25 pack years; Not specified, alcohol use; Adherence, not documented, lisinopril, liraglutide (which is an herbal supplement used for mood); Current, takes St. John's wort daily.

    ·
    **Relevant Medical History:** Hypertension (on lisinopril 40 mg daily) and type 2 diabetes (on liraglutide 0.6 mg subcutaneously daily).

    ·
    **Current Diagnoses:**

    · Severe hypercholesterolemia (LDL 180mg/dL)

    · Mixed hyperlipidaemia (total cholesterol = 260 mg/dL, TG = 185 mg/dL)

    · Diabetes + hypertension + smoking + obesity is considered to be high-risk atherosclerotic cardiovascular disease (ASCVD) equivalent.

    · Overweight/obesity (height 5’9”, weight 204 lbs → BMI ≈ 30.1 kg/m²)

    ·
    **Pathophysiological Changes (e.g., renal, heart, or liver failure):** No renal failure, heart failure or liver failure reported; diabetes causes endothelial dysfunction, accelerated atherosclerosis, and LDL particle retention; smoking causes LDL to oxidize and HDL to decrease; cardiovascular benefit of liraglutide is not fully compensated for by dyslipidemia.

    ### 2. Medication Plan

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dosage and Route:** 40 mg orally

    ·
    **Frequency:** Once daily in the evening

    ·
    **Rationale for Selection (including patient-specific factors):** Atorvastatin 40 mg is a high-intensity statin, which lowers LDL by ≥50% (Grundy et al., 2019). The 2018 ACC/AHA cholesterol guideline recommends that persons with diabetes age 40-75 years who have multiple ASCVD risk factors (e.g. hypertension, smoking, obesity, LDL ≥70 mg/dL) should be treated with high-intensity statin therapy, even without the use of a risk calculator (Bhattacharya, 2026). Another risk factor for this patient is his LDL of 180 mg/dL, which is considered severe (LDL ≥190 mg/dL is considered severe; 180 mg/dL is borderline severe with multiple risks). The use of a statin is equally beneficial irrespective of age, gender or ethnicity, as would be further increased at 47 years and male (if applicable) and African American ethnicity (if applicable). Atorvastatin is more commonly used than simvastatin as this is a moderate dose and simvastatin 80mg is no longer recommended as it carries the risk of myopathy. Furthermore, there is greater and more stable LDL lowering with atorvastatin. Most importantly, the patient should stop taking St. John's wort, which is a strong inducer of CYP3A4, and decreases the serum levels of atorvastatin and the reduction in LDL.

    ·
    **Potential Drug Interactions or Contraindications:**

    · St. John's wort is an inducer of CYP3A4 which decreases atorvastatin AUC by ~40% and may result in therapeutic failure and ongoing high ASCVD risk (Chan et al., 2025).

    · No contraindications with lisinopril or liraglutide.

    · Smoking by itself does not interact directly, it does however increase LDL oxidation and decrease HDL.

    · Stay away from gemfibrozil (risks of myopathy); good old fenofibrate can be used if triglycerides are still > 500 mg/dL.

    · Relative contraindication: Active liver disease (not reported).

    ·
    **Monitoring Parameters:**

    · Baseline: Lipid panel, liver function tests (ALT, AST), creatine kinase (CK)

    · Repeat lipid profile after 4–12 weeks to evaluate LDL response to treatment and adherence (Bhattacharya, 2026).

    · Ongoing: CK only if patient complains of unexplainable muscle pain, weakness or dark urine.

    · Once every 6-12 months: LFTs; stop if ALT/AST is more than 3 times the upper limit of normal.

    · Behavioral Monitoring: Evaluate smoking status and St. John's wort use at each patient visit.

    ### 3. Ethical and Legal Considerations

    Several ethical and legal principles apply to KU’s personalized medication plan.

    · Informed consent: Provider needs to explain that St. John's wort decreases the effectiveness of atorvastatin in lowering LDL cholesterol, thus the risk of heart attack or stroke (Mefford et al., 2021). The patient can refuse to stop the herb but the provider should record this decision and think about using an alternative statin that is not as reliant on CYP3A4 such as pravastatin (which is less effective).

    · Patient autonomy is recognized by offering evidence-based choices, rather than pressuring. When prescribing St. John's wort, the provider may still prescribe atorvastatin, but will have to monitor and counsel for residual risk if KU decides to continue prescribing St. John's wort.

    · Cultural sensitivity: Some patients take herbal medicines such as St. John's wort in the context of their culture belief. The provider should enquire about the use of supplements in a respectful way, without using judgmental language, and should recognize that some patients may not be accepting conventional treatment, and have a distrust of it.

    · Legal issues: The prescriber (NP or physician) must practice within the scope of practice for statins in their state, and have the power to stop prescribing supplements. Not checking for herb-drug interactions may be a failure to meet the standard of care and be legally liable (Guyton, 2021). Moreover, it's legal to document counselling on smoking cessation, as smoking is a risk factor that can be modified, and statins don't fully counteract it.

    · Equity and conformance to guidelines: The ACC/AHA guidelines apply to all ethnicities/genders and the cost and accessibility shouldn't be barriers (atorvastatin is generic and low cost) (Blumenthal et al., 2026).

    ### 4. Complete Medication Order

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dose:** 40 mg

    ·
    **Route:** Oral

    ·
    **Frequency:** Once a day in the evening

    ·
    **Special Instructions:**

    · Stop St. John's wort because of important drug interaction that decreases the cholesterol-lowering effect.

    · May be taken with or without food. Dosage in the evening might be more beneficial to the reduction of LDL.

    · Have fasted blood lipid panel and liver function tests repeated in 6 weeks.

    · Call a doctor for any unexplained muscle pain or tenderness, weakness, or dark-colored urine or fatigue.

    · Strongly recommend smoking cessation counseling – refer to tobacco cessation program.

    · Use lisinopril 40 mg once a day and liraglutide 0.6 mg subcutaneously once daily, as needed.

    ## References

    Bhattacharya, R. (2026).
    _New cholesterol guidelines | mass general brigham_. Massgeneralbrigham.org. https://www.massgeneralbrigham.org/en/about/newsroom/articles/new-cholesterol-guidelines

    Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., & Mora, S. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.
    _JACC_,
    _87_(19). https://doi.org/10.1016/j.jacc.2025.11.016

    Chan, W.-J. J., Hunter, J., McLachlan, A. J., & Harnett, J. E. (2025). Consumer purchasing behaviour: oral contraceptives with Hypericum perforatum, and atorvastatin with Camellia sinensis: an Australia-wide basket analysis.
    _Drugs & Therapy Perspectives_,
    _41_, 354–362. https://doi.org/10.1007/s40267-025-01167-z

    Guyton, J. R. (2021). From the editor: Plagues and the ancient legacy of epimenides.
    _Journal of Clinical Lipidology_,
    _14_(3), 271–272. https://doi.org/10.1016/j.jacl.2020.05.004

    Mefford, B., Donaldson, J. C., & Bissell, B. D. (2021). The immunomodulatory effects of opioids and implications for intensive care unit populations.
    _Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy_,
    _41_(8), 668–675. https://doi.org/10.1002/phar.2602

    **## case.docx**

    KU is a 47 year old male following up on his lab that were drawn last week. He smokes 1 pack per day. He is currently on lisinopril 40mg po daily, liraglutide (Victoza) 0.6mg subcutaneously once daily and St. John's Wort. Fasting lipid profile shows total cholesterol 260mg/dL, LDL 180mg/dL, and TG 185mg/dL. He is 5'9' and weights 204lbs.

    **## ASSESSMECARDIOVASCULARSYSTEMPATIENTCASEPART2.docx**

    ASSESSMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 2

    ![A computer with a paper on it AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    In Part 2 of the Cardiovascular System Patient Case, you will synthesize your learning into a succinct
    **elevator speech**, presenting your patient plan and reflecting on how new insights from the module inform your clinical approach.

    This assignment challenges you to
    **communicate complex pharmacotherapeutic decisions** clearly and concisely, demonstrating your ability to
    **adapt treatment strategies** based on evolving evidence and patient needs. Use the study questions to identify key information and ensure your presentation is both comprehensive and focused.

    ![A blue and white logo AI-generated content may be incorrect.](https://www.sweetstudy.com/questions/assessment-cardiovascular-system-patient-case-part-2)

    **Level 1: No AI Permitted**

    · AI tools may
    **not** be used at any stage

    · Common for clinical documentation or performancebased work

    RESOURCES

    Be sure to review the Learning Resources before completing this assessment.

    [Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290075?module_item_id=9903145)

    **To prepare:**

    · Complete the Cardiovascular System Patient Case, Part 1

    · Consider the important information to present from your patient plan

    BY SUNDAY OF WEEK 2

    Submit a 3-minute elevator speech recording using a slide deck to highlight the important information from your patient plan.

    Imagine you are giving your preceptor an update on the case. In your presentation, explore how your treatment plan would change based on what you learned this week. This presentation should be no more than 3 minutes.

    ## image1.png

    ## image2.png

    **## MD1Assgn1_Edobor_J.docx**

    1

    ## Patient Case Study Template

    Jane Edobor

    Walden University

    Dr Veleka Grady

    Advance pharmacology

    May 29, 2026

    ## Patient Case Study Template

    ### 1. Patient Profile

    ·
    **Age:** 47 years

    ·
    **Gender:** Male

    ·
    **Ethnicity:** Not specified

    ·
    **Relevant Genetics (if available):** None reported, no familial hypercholesterolemia or markers for statin sensitivity (e.g., SLCO1B1 variants).

    ·
    **Behavioral Factors (e.g., smoking, alcohol, adherence):** Current smoker, approximately 25 pack years; Not specified, alcohol use; Adherence, not documented, lisinopril, liraglutide (which is an herbal supplement used for mood); Current, takes St. John's wort daily.

    ·
    **Relevant Medical History:** Hypertension (on lisinopril 40 mg daily) and type 2 diabetes (on liraglutide 0.6 mg subcutaneously daily).

    ·
    **Current Diagnoses:**

    · Severe hypercholesterolemia (LDL 180mg/dL)

    · Mixed hyperlipidaemia (total cholesterol = 260 mg/dL, TG = 185 mg/dL)

    · Diabetes + hypertension + smoking + obesity is considered to be high-risk atherosclerotic cardiovascular disease (ASCVD) equivalent.

    · Overweight/obesity (height 5’9”, weight 204 lbs → BMI ≈ 30.1 kg/m²)

    ·
    **Pathophysiological Changes (e.g., renal, heart, or liver failure):** No renal failure, heart failure or liver failure reported; diabetes causes endothelial dysfunction, accelerated atherosclerosis, and LDL particle retention; smoking causes LDL to oxidize and HDL to decrease; cardiovascular benefit of liraglutide is not fully compensated for by dyslipidemia.

    ### 2. Medication Plan

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dosage and Route:** 40 mg orally

    ·
    **Frequency:** Once daily in the evening

    ·
    **Rationale for Selection (including patient-specific factors):** Atorvastatin 40 mg is a high-intensity statin, which lowers LDL by ≥50% (Grundy et al., 2019). The 2018 ACC/AHA cholesterol guideline recommends that persons with diabetes age 40-75 years who have multiple ASCVD risk factors (e.g. hypertension, smoking, obesity, LDL ≥70 mg/dL) should be treated with high-intensity statin therapy, even without the use of a risk calculator (Bhattacharya, 2026). Another risk factor for this patient is his LDL of 180 mg/dL, which is considered severe (LDL ≥190 mg/dL is considered severe; 180 mg/dL is borderline severe with multiple risks). The use of a statin is equally beneficial irrespective of age, gender or ethnicity, as would be further increased at 47 years and male (if applicable) and African American ethnicity (if applicable). Atorvastatin is more commonly used than simvastatin as this is a moderate dose and simvastatin 80mg is no longer recommended as it carries the risk of myopathy. Furthermore, there is greater and more stable LDL lowering with atorvastatin. Most importantly, the patient should stop taking St. John's wort, which is a strong inducer of CYP3A4, and decreases the serum levels of atorvastatin and the reduction in LDL.

    ·
    **Potential Drug Interactions or Contraindications:**

    · St. John's wort is an inducer of CYP3A4 which decreases atorvastatin AUC by ~40% and may result in therapeutic failure and ongoing high ASCVD risk (Chan et al., 2025).

    · No contraindications with lisinopril or liraglutide.

    · Smoking by itself does not interact directly, it does however increase LDL oxidation and decrease HDL.

    · Stay away from gemfibrozil (risks of myopathy); good old fenofibrate can be used if triglycerides are still > 500 mg/dL.

    · Relative contraindication: Active liver disease (not reported).

    ·
    **Monitoring Parameters:**

    · Baseline: Lipid panel, liver function tests (ALT, AST), creatine kinase (CK)

    · Repeat lipid profile after 4–12 weeks to evaluate LDL response to treatment and adherence (Bhattacharya, 2026).

    · Ongoing: CK only if patient complains of unexplainable muscle pain, weakness or dark urine.

    · Once every 6-12 months: LFTs; stop if ALT/AST is more than 3 times the upper limit of normal.

    · Behavioral Monitoring: Evaluate smoking status and St. John's wort use at each patient visit.

    ### 3. Ethical and Legal Considerations

    Several ethical and legal principles apply to KU’s personalized medication plan.

    · Informed consent: Provider needs to explain that St. John's wort decreases the effectiveness of atorvastatin in lowering LDL cholesterol, thus the risk of heart attack or stroke (Mefford et al., 2021). The patient can refuse to stop the herb but the provider should record this decision and think about using an alternative statin that is not as reliant on CYP3A4 such as pravastatin (which is less effective).

    · Patient autonomy is recognized by offering evidence-based choices, rather than pressuring. When prescribing St. John's wort, the provider may still prescribe atorvastatin, but will have to monitor and counsel for residual risk if KU decides to continue prescribing St. John's wort.

    · Cultural sensitivity: Some patients take herbal medicines such as St. John's wort in the context of their culture belief. The provider should enquire about the use of supplements in a respectful way, without using judgmental language, and should recognize that some patients may not be accepting conventional treatment, and have a distrust of it.

    · Legal issues: The prescriber (NP or physician) must practice within the scope of practice for statins in their state, and have the power to stop prescribing supplements. Not checking for herb-drug interactions may be a failure to meet the standard of care and be legally liable (Guyton, 2021). Moreover, it's legal to document counselling on smoking cessation, as smoking is a risk factor that can be modified, and statins don't fully counteract it.

    · Equity and conformance to guidelines: The ACC/AHA guidelines apply to all ethnicities/genders and the cost and accessibility shouldn't be barriers (atorvastatin is generic and low cost) (Blumenthal et al., 2026).

    ### 4. Complete Medication Order

    ·
    **Medication Name:** Atorvastatin

    ·
    **Dose:** 40 mg

    ·
    **Route:** Oral

    ·
    **Frequency:** Once a day in the evening

    ·
    **Special Instructions:**

    · Stop St. John's wort because of important drug interaction that decreases the cholesterol-lowering effect.

    · May be taken with or without food. Dosage in the evening might be more beneficial to the reduction of LDL.

    · Have fasted blood lipid panel and liver function tests repeated in 6 weeks.

    · Call a doctor for any unexplained muscle pain or tenderness, weakness, or dark-colored urine or fatigue.

    · Strongly recommend smoking cessation counseling – refer to tobacco cessation program.

    · Use lisinopril 40 mg once a day and liraglutide 0.6 mg subcutaneously once daily, as needed.

    ## References

    Bhattacharya, R. (2026).
    _New cholesterol guidelines | mass general brigham_. Massgeneralbrigham.org. https://www.massgeneralbrigham.org/en/about/newsroom/articles/new-cholesterol-guidelines

    Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., & Mora, S. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.
    _JACC_,
    _87_(19). https://doi.org/10.1016/j.jacc.2025.11.016

    Chan, W.-J. J., Hunter, J., McLachlan, A. J., & Harnett, J. E. (2025). Consumer purchasing behaviour: oral contraceptives with Hypericum perforatum, and atorvastatin with Camellia sinensis: an Australia-wide basket analysis.
    _Drugs & Therapy Perspectives_,
    _41_, 354–362. https://doi.org/10.1007/s40267-025-01167-z

    Guyton, J. R. (2021). From the editor: Plagues and the ancient legacy of epimenides.
    _Journal of Clinical Lipidology_,
    _14_(3), 271–272. https://doi.org/10.1016/j.jacl.2020.05.004

    Mefford, B., Donaldson, J. C., & Bissell, B. D. (2021). The immunomodulatory effects of opioids and implications for intensive care unit populations.
    _Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy_,
    _41_(8), 668–675. https://doi.org/10.1002/phar.2602

  • [Solved] Nursing Nursing Homework

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    Looking for someone to do my nursing assignment **files (1)** – ## OlderAdultCommunityAssessmentPaperPart2Instruction-AIver-1-1.docx **## OlderAdultCommunityAssessmentPaperPart2Instruction-AIver-1-1.docx** ## Older Adult Community Assessment Paper Part Two Moving forward with Mrs. E’s scenario. From…

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Looking for someone to do my nursing assignment

    **files (1)**

    – ## OlderAdultCommunityAssessmentPaperPart2Instruction-AIver-1-1.docx

    **## OlderAdultCommunityAssessmentPaperPart2Instruction-AIver-1-1.docx**

    ## Older Adult Community Assessment Paper Part Two

    Moving forward with Mrs. E’s scenario. From the point of view of an older adult, use the information you gathered in part one to evaluate your neighborhood in terms of how adequately it will meet the present and anticipated future needs of older adults, such as Mrs. E.

    Write a paper on this using APA format. Use the seventh edition APA. This is an academic APA paper from the view of an outside person (Write in 3rd person; avoid “I,” “You,” or “We” statements). Avoid telling a story of yourself and your dog. Avoid personal information about your family. Avoid material on older adults that does not apply to the community (a half-page on hypertension from the Mayo Clinic does not belong; focus on the community and older adults). Your paper should be a minimum of
    **three pages** and a maximum of
    **five pages,** double-spaced, not counting the cover page, appendix, or references. Students must use at least
    **three current academic articles (that are peer-reviewed) in addition to supporting their view of the neighborhood.** These references should concern
    **the** characteristics and needs of older adults. Crime rates should be reported as incidents per 1000 or 100,000 inhabitants. Crime rates should be reported using government sources. Facts that are not common knowledge should be supported with a citation. One of those references can be your textbook.
    **Remember to add the corrected version of the table you did in week two as an appendix and to mention it in the paper.**

    All submissions will be checked for plagiarism. If any is detected without an appropriate citation, the student will receive zero points in that area of the assignment and may be referred to the Office of Student Conduct (OSC) for academic dishonesty. Also, if you are repeating this class, remember you can’t use your old assignment. You must select a different location; otherwise, you will violate student conduct and be referred to the Office of Student Conduct (OSC).

    **See Canvas for the grading rubric of the Older Adult Community Assessment Paper and more instructions.**

    **## OlderAdultCommunityAssessmentPaperPart2Instruction-AIver-1-1.docx**

    ## Older Adult Community Assessment Paper Part Two

    Moving forward with Mrs. E’s scenario. From the point of view of an older adult, use the information you gathered in part one to evaluate your neighborhood in terms of how adequately it will meet the present and anticipated future needs of older adults, such as Mrs. E.

    Write a paper on this using APA format. Use the seventh edition APA. This is an academic APA paper from the view of an outside person (Write in 3rd person; avoid “I,” “You,” or “We” statements). Avoid telling a story of yourself and your dog. Avoid personal information about your family. Avoid material on older adults that does not apply to the community (a half-page on hypertension from the Mayo Clinic does not belong; focus on the community and older adults). Your paper should be a minimum of
    **three pages** and a maximum of
    **five pages,** double-spaced, not counting the cover page, appendix, or references. Students must use at least
    **three current academic articles (that are peer-reviewed) in addition to supporting their view of the neighborhood.** These references should concern
    **the** characteristics and needs of older adults. Crime rates should be reported as incidents per 1000 or 100,000 inhabitants. Crime rates should be reported using government sources. Facts that are not common knowledge should be supported with a citation. One of those references can be your textbook.
    **Remember to add the corrected version of the table you did in week two as an appendix and to mention it in the paper.**

    All submissions will be checked for plagiarism. If any is detected without an appropriate citation, the student will receive zero points in that area of the assignment and may be referred to the Office of Student Conduct (OSC) for academic dishonesty. Also, if you are repeating this class, remember you can’t use your old assignment. You must select a different location; otherwise, you will violate student conduct and be referred to the Office of Student Conduct (OSC).

    **See Canvas for the grading rubric of the Older Adult Community Assessment Paper and more instructions.**

  • [Solved] Journal Response MODULE 6-865

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    OVERVIEW Data analysis is a process that dives into raw information to transform it to useful **files (2)** – ## Module6JournalQuestion.docx – ## Module6JournalRubric.docx **## Module6JournalQuestion.docx** OVERVIEW Data analysis is a process that dives into raw information to transform it to useful…

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    OVERVIEW

    Data analysis is a process that dives into raw information to transform it to useful

    **files (2)**

    – ## Module6JournalQuestion.docx

    – ## Module6JournalRubric.docx

    **## Module6JournalQuestion.docx**

    OVERVIEW

    Data analysis is a process that dives into raw information to transform it to useful, applicable knowledge. Healthcare informatics specializes in bridging the gap between data and patient care to investigate what is known and how change impacts patient outcomes. The visual representation of data can serve as a powerful tool to promote and sustain change.

    **Journal Question:**

    Reflect on the new knowledge you have gained during this course so far and the skills you are building. How will these support your role as the DNP leader in administrative and clinical settings? What resources will you use to continue to build skills around data use?

    **Journal Response Expectations**

    Each short-answer Journal response will be a minimum of 300 words; no citation, reference, or APA style is necessary.

    **REFERENCES**

    McGonigle, D., & Mastrian, K. (2021).
    _Nursing informatics and the foundation of knowledge_(5th ed.). Jones and Bartlett. ISBN:9781284220469. Read chapters 21 & 23.

    **ADDITIONAL RESOURCE**

    Schwartzberg, J. (2020).
    _Present your data like a pro._ Harvard Business Review: Analytics and Data Science
    _._ [https://hbr.org/2020/02/present-your-data-like-a-pro](https://hbr.org/2020/02/present-your-data-like-a-pro)

    Microsoft. (2022).
    _Excel video training_.
    [https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb](https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb)

    **## Module6JournalRubric.docx**

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    **Graduate Journal Question Rubric v1**

    Course: DNP865 Sect1 Healthcare Technologies and Informatics

    Criteria

    **Does Not Meet**

    **Expectations**

    **Approaches**

    **Expectations**

    **Meets Expectations**

    **Exceeds Expectations**

    **Criterion Score**

    Claim/Quality of

    Information

    Weight: 40%

    / 8

    points

    0

    **pts**

    **(0**

    **)**

    Response to quiz

    question is missing

    or inaccurate.

    Answer is inaccurate

    and does not ad

    –

    dress the prompt.

    points

    2.5

    **(5.6**

    **pts**

    **)**

    Response to quiz

    question is missing

    key elements.

    Answer is partially

    inaccurate and

    misses elements in

    the prompt. Claims

    are lacking informa

    –

    tion to be fully

    thought out.

    points

    6.4

    **(6.4**

    **pts**

    **)**

    Response to quiz

    question is appropri

    –

    ate and accurate.

    Answer is appropri

    –

    ate and responses

    to the prompt.

    Claims are

    appropriate.

    8

    points

    **pts**

    **(8**

    **)**

    Response to quiz

    question is thorough

    and detailed.

    Answer is clear and

    concise and re

    –

    sponses to all as

    –

    pects of the prompt.

    Claims are justified

    and plausible.

    ![](https://www.sweetstudy.com/questions/journal-response-module-6-865)

    **Overall Score**

    **Level 1**

    0

    points minimum

    **Level 2**

    14

    points minimum

    **Level 3**

    16

    points minimum

    **Level 4**

    20

    points minimum

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    1/3

    ## image1.png

    **## Module6JournalRubric.docx**

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    **Graduate Journal Question Rubric v1**

    Course: DNP865 Sect1 Healthcare Technologies and Informatics

    Criteria

    **Does Not Meet**

    **Expectations**

    **Approaches**

    **Expectations**

    **Meets Expectations**

    **Exceeds Expectations**

    **Criterion Score**

    Claim/Quality of

    Information

    Weight: 40%

    / 8

    points

    0

    **pts**

    **(0**

    **)**

    Response to quiz

    question is missing

    or inaccurate.

    Answer is inaccurate

    and does not ad

    –

    dress the prompt.

    points

    2.5

    **(5.6**

    **pts**

    **)**

    Response to quiz

    question is missing

    key elements.

    Answer is partially

    inaccurate and

    misses elements in

    the prompt. Claims

    are lacking informa

    –

    tion to be fully

    thought out.

    points

    6.4

    **(6.4**

    **pts**

    **)**

    Response to quiz

    question is appropri

    –

    ate and accurate.

    Answer is appropri

    –

    ate and responses

    to the prompt.

    Claims are

    appropriate.

    8

    points

    **pts**

    **(8**

    **)**

    Response to quiz

    question is thorough

    and detailed.

    Answer is clear and

    concise and re

    –

    sponses to all as

    –

    pects of the prompt.

    Claims are justified

    and plausible.

    ![](https://www.sweetstudy.com/questions/journal-response-module-6-865)

    **Overall Score**

    **Level 1**

    0

    points minimum

    **Level 2**

    14

    points minimum

    **Level 3**

    16

    points minimum

    **Level 4**

    20

    points minimum

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    1/3

    ## image1.png

    **## Module6JournalQuestion.docx**

    OVERVIEW

    Data analysis is a process that dives into raw information to transform it to useful, applicable knowledge. Healthcare informatics specializes in bridging the gap between data and patient care to investigate what is known and how change impacts patient outcomes. The visual representation of data can serve as a powerful tool to promote and sustain change.

    **Journal Question:**

    Reflect on the new knowledge you have gained during this course so far and the skills you are building. How will these support your role as the DNP leader in administrative and clinical settings? What resources will you use to continue to build skills around data use?

    **Journal Response Expectations**

    Each short-answer Journal response will be a minimum of 300 words; no citation, reference, or APA style is necessary.

    **REFERENCES**

    McGonigle, D., & Mastrian, K. (2021).
    _Nursing informatics and the foundation of knowledge_(5th ed.). Jones and Bartlett. ISBN:9781284220469. Read chapters 21 & 23.

    **ADDITIONAL RESOURCE**

    Schwartzberg, J. (2020).
    _Present your data like a pro._ Harvard Business Review: Analytics and Data Science
    _._ [https://hbr.org/2020/02/present-your-data-like-a-pro](https://hbr.org/2020/02/present-your-data-like-a-pro)

    Microsoft. (2022).
    _Excel video training_.
    [https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb](https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb)

    **## Module6JournalRubric.docx**

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    **Graduate Journal Question Rubric v1**

    Course: DNP865 Sect1 Healthcare Technologies and Informatics

    Criteria

    **Does Not Meet**

    **Expectations**

    **Approaches**

    **Expectations**

    **Meets Expectations**

    **Exceeds Expectations**

    **Criterion Score**

    Claim/Quality of

    Information

    Weight: 40%

    / 8

    points

    0

    **pts**

    **(0**

    **)**

    Response to quiz

    question is missing

    or inaccurate.

    Answer is inaccurate

    and does not ad

    –

    dress the prompt.

    points

    2.5

    **(5.6**

    **pts**

    **)**

    Response to quiz

    question is missing

    key elements.

    Answer is partially

    inaccurate and

    misses elements in

    the prompt. Claims

    are lacking informa

    –

    tion to be fully

    thought out.

    points

    6.4

    **(6.4**

    **pts**

    **)**

    Response to quiz

    question is appropri

    –

    ate and accurate.

    Answer is appropri

    –

    ate and responses

    to the prompt.

    Claims are

    appropriate.

    8

    points

    **pts**

    **(8**

    **)**

    Response to quiz

    question is thorough

    and detailed.

    Answer is clear and

    concise and re

    –

    sponses to all as

    –

    pects of the prompt.

    Claims are justified

    and plausible.

    ![](https://www.sweetstudy.com/questions/journal-response-module-6-865)

    **Overall Score**

    **Level 1**

    0

    points minimum

    **Level 2**

    14

    points minimum

    **Level 3**

    16

    points minimum

    **Level 4**

    20

    points minimum

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    1/3

    ## image1.png

    **## Module6JournalQuestion.docx**

    OVERVIEW

    Data analysis is a process that dives into raw information to transform it to useful, applicable knowledge. Healthcare informatics specializes in bridging the gap between data and patient care to investigate what is known and how change impacts patient outcomes. The visual representation of data can serve as a powerful tool to promote and sustain change.

    **Journal Question:**

    Reflect on the new knowledge you have gained during this course so far and the skills you are building. How will these support your role as the DNP leader in administrative and clinical settings? What resources will you use to continue to build skills around data use?

    **Journal Response Expectations**

    Each short-answer Journal response will be a minimum of 300 words; no citation, reference, or APA style is necessary.

    **REFERENCES**

    McGonigle, D., & Mastrian, K. (2021).
    _Nursing informatics and the foundation of knowledge_(5th ed.). Jones and Bartlett. ISBN:9781284220469. Read chapters 21 & 23.

    **ADDITIONAL RESOURCE**

    Schwartzberg, J. (2020).
    _Present your data like a pro._ Harvard Business Review: Analytics and Data Science
    _._ [https://hbr.org/2020/02/present-your-data-like-a-pro](https://hbr.org/2020/02/present-your-data-like-a-pro)

    Microsoft. (2022).
    _Excel video training_.
    [https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb](https://support.microsoft.com/en-us/office/excel-video-training-9bc05390-e94c-46af-a5b3-d7c22f6990bb)

    **## Module6JournalRubric.docx**

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    5/20/26, 8:45 PM Preview Rubric: Graduate Journal Question Rubric v1 – DNP865 Sect1 Healthcare Technologies and Informatics – Aspen University Classroom

    **Graduate Journal Question Rubric v1**

    Course: DNP865 Sect1 Healthcare Technologies and Informatics

    Criteria

    **Does Not Meet**

    **Expectations**

    **Approaches**

    **Expectations**

    **Meets Expectations**

    **Exceeds Expectations**

    **Criterion Score**

    Claim/Quality of

    Information

    Weight: 40%

    / 8

    points

    0

    **pts**

    **(0**

    **)**

    Response to quiz

    question is missing

    or inaccurate.

    Answer is inaccurate

    and does not ad

    –

    dress the prompt.

    points

    2.5

    **(5.6**

    **pts**

    **)**

    Response to quiz

    question is missing

    key elements.

    Answer is partially

    inaccurate and

    misses elements in

    the prompt. Claims

    are lacking informa

    –

    tion to be fully

    thought out.

    points

    6.4

    **(6.4**

    **pts**

    **)**

    Response to quiz

    question is appropri

    –

    ate and accurate.

    Answer is appropri

    –

    ate and responses

    to the prompt.

    Claims are

    appropriate.

    8

    points

    **pts**

    **(8**

    **)**

    Response to quiz

    question is thorough

    and detailed.

    Answer is clear and

    concise and re

    –

    sponses to all as

    –

    pects of the prompt.

    Claims are justified

    and plausible.

    ![](https://www.sweetstudy.com/questions/journal-response-module-6-865)

    **Overall Score**

    **Level 1**

    0

    points minimum

    **Level 2**

    14

    points minimum

    **Level 3**

    16

    points minimum

    **Level 4**

    20

    points minimum

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    https://classroom.aspen.edu/d2l/le/content/119358/viewContent/6335766/View 1/3

    1/3

    ## image1.png

  • [Solved] Windshield survey

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    Need help with formulating ideas for assignment. Instructions for assignment and rubric is posted down below. – [\ \ Module2-WindshieldSurveyPaper-Su26NURS34801-02PublicHealthNursing-.pdf](https://www.sweetstudy.com/files/module2-windshieldsurveypaper-su26nurs34801-02publichealthnursing-pdf "Modul…

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Need help with formulating ideas for assignment. Instructions for assignment and rubric is posted down below.

    – [\
    \
    Module2-WindshieldSurveyPaper-Su26NURS34801-02PublicHealthNursing-.pdf](https://www.sweetstudy.com/files/module2-windshieldsurveypaper-su26nurs34801-02publichealthnursing-pdf "Module2-WindshieldSurveyPaper-Su26NURS34801-02PublicHealthNursing-.pdf")
    – [\
    \
    IMG_0967.jpeg](https://www.sweetstudy.com/files/img-0967-jpeg-10557709 "IMG_0967.jpeg")

  • [Solved] Wk2 assign psychotherapy

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    In-depth study guidance and analytical solution covering Wk2 assign psychotherapy.

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Full assignment prompt and step-by-step guidance are included in the downloadable solution file.

  • [Solved] Wk2 assign Prac psychotherapy

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    Record the required information in each area of the Practicum Experience Plan template, including 3–4 **measurable** practicum learning objectives you will use to facilitate your learning during the practicum experience.

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Record the required information in each area of the Practicum Experience Plan template, including 3–4 **measurable** practicum learning objectives you will use to facilitate your learning during the practicum experience.

  • [Solved] Cardiovascular system

    ✓ Verified Academic Solution Available

    Executive Solution Overview

    In-depth study guidance and analytical solution covering Cardiovascular system.

    Instant Solution Download

    $6.99

    Immediate access to the full model answer, formatted citations, and rubric breakdown.

    Need a Fresh Custom Paper?

    Have this question answered from scratch according to your specific instructions and deadline.

    Order on TutorsGallery →

    Assignment Prompt & Instructions

    Full assignment prompt and step-by-step guidance are included in the downloadable solution file.